Preclinical evaluation on human platelet lysate for the treatment of secondary injury following intracerebral hemorrhage.

Intracerebral hemorrhage (ICH) is a condition with high mortality and disability. Secondary injury processes following ICH include neuroinflammation, oxidative stress, and neuronal apoptosis. Human platelet lysate (HPL), derived from crushed platelets, is rich in cytokines and has demonstrated therapeutic potential in neurological disorders in several studies. However, studies on HPL for ICH remain limited. In this study, we prepared HPL for intranasal administration in ICH treatment. We determined the concentration of growth factors in HPL, validated the targeting of HPL, and established a mouse model of ICH. We observed that HPL improved neuromotor deficits in ICH mice. Barnes maze training showed that HPL enhanced spatial memory and learning ability in mice. Furthermore, HPL reduced neuroinflammation, brain edema, oxidative stress, neuronal apoptosis, and neural axonal damage. Additionally, 5 % HPL demonstrated potent functional activity with no cytotoxicity in SH-5YSY cell cultures. These findings indicate that HPL is a promising therapeutic approach for mitigating secondary brain injury following ICH.